Bristol Myers Squibb Announces Early Participation Results, Upsizing and Early Settlement of Tender Offers Pharmaceutical Investing
Dragonfly Therapeutics Announces Achievement of Phase 1 Clinical Development Milestone for IL-12 Investigational Immunotherapy Program with Bristol Myers Squibb Pharmaceutical Investing
Gilead Receives Complete Response Letter From U.S. FDA for Investigational Lenacapavir Due to Vial Compatability Issues Pharmaceutical Investing
Cardiol Therapeutics Receives Clearance from the FDA and Regulatory Agencies in Brazil and Mexico for Important Protocol Amendments Designed to Expedite Patient Enrollment in the LANCER Trial Pharmaceutical Investing
BELLUS Health to Participate in the Cowen & Co. 42nd Annual Health Care Conference Pharmaceutical Investing
BioHarvest CEO Ilan Sobel: Disrupting Industries with Unique Products and Therapeutic Solutions Biotech Investing
AbbVie Provides Update Regarding SKYRIZI® for the Treatment of Moderate to Severe Crohn's Disease in the U.S. Pharmaceutical Investing
